Request Demo

Last update 27 Jan 2026

Emtricitabine

Last update 27 Jan 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, (−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (−)-2'-deoxy-5-fluoro-3'-thiacytidine

+ [18]

Target

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication

Aicardi-Goutieres SyndromeCoinfectionHepatitis B+ [5]

Originator Organization

Gilead Sciences, Inc.

Active Organization

Gilead Sciences Ireland UC

Gilead Sciences, Inc.

Hebei Medical University Pharmaceutical Factory

Inactive Organization

Triangle Pharmaceuticals, Inc.

License Organization

Gilead Sciences, Inc.

Triangle Pharmaceuticals, Inc.Royalty Pharma AG

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (02 Jul 2003),

HIV Infections

RegulationOrphan Drug (Japan)

Structure/Sequence

Molecular FormulaC8H10FN3O3S

InChIKeyXQSPYNMVSIKCOC-NTSWFWBYSA-N

CAS Registry143491-57-0

164

Clinical Trials associated with Emtricitabine

NCT03304717

/ WithdrawnPhase 1/2IIT

Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome

The overall objectives are to explore the safety and efficacy of Reverse Transcriptase Inhibitors Tenofovir (TDF)/ Emtricitabine (FTC) administered in AGS affected children 2 to 18 years of age.

Start Date01 Dec 2025

Sponsor / Collaborator

The Children's Hospital of Philadelphia

[+5]

NCT07062614

/ Active, not recruitingNot ApplicableIIT

Exploration of Intra-individual Variability of Exposure to Emtricitabine and Lamivudine in Hair With a View to Validating the Value of This Matrix as a Diagnostic Tool for Partial and/or Total Non-compliance With Antiretroviral Treatment

Treatment adherence is defined by compliance with the dosage schedule (i.e., dose per dose and number of doses per day), as well as the duration of administration (i.e., number of days during which the dosage schedule must be followed).
Treatment adherence determines the therapeutic efficacy and the absence of toxicity of the prescribed medication. However, this adherence is far from being respected even by patients with serious pathologies such as patients living with HIV (PLWHIV). However, among PLWHIV, non-adherence is a significant source of virological failure and is difficult to assess because it is most often based on what the patient reports to their doctor. A currently used approach consists of determining the drug concentration in the blood and possibly that of its metabolite(s). However, determining a drug's blood concentration presents two major pitfalls: (i) it is necessary to take a blood sample, which remains an invasive procedure for the patient; (ii) for the vast majority of drugs, if the patient scrupulously adheres to the dosage schedule a few days before the blood sample is taken, the drug concentration is most often within the expected range. Therefore, a concentration in the reference range does not exclude partial or even total non-compliance between two medical visits. Saliva is a more easily accessible matrix than blood. However, the same representativeness problem is encountered due to the fact that saliva is in almost instantaneous equilibrium with blood.
Urine could be used to assess compliance. However, this requires multiple urine collections between two doses. This constraint is not compatible with the organization of clinical services. The objective is to determine intra-individual variability in the amount of antiretroviral (ARV) in different segments of the same strand of hair during periods of full treatment adherence.
This objective is preliminary to the use of hair as a tool for detecting treatment non-adherence in patients.
Two reference antiretroviral molecules will be documented: Emtricitabine and Lamivudine, as they are present, one or the other, in the majority of antiretroviral combination strategies.

Start Date03 Jul 2025

Sponsor / Collaborator

Toulouse University Hospital

NCT07210528

/ RecruitingPhase 1IIT

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Emtricitabine and Descovy in Patients With Mild Cognitive Impairment.

Recent studies have identified an association between Alzheimer's Disease (AD) and an expansion of DNA content in the brain (prefrontal cortex). This additional DNA content appears to be derived from reverse transcriptase (RT) activity that incorporates genomic cDNAs (gencDNAs) into chromosomes, resulting in multiple copies of full length and shorter cDNAs involving many genes - including the causal AD gene amyloid precursor protein (APP). Accumulation of these APP gencDNAs is associated with AD.
This identifies RT as a promising therapeutic target for the attenuation of AD progression through existing reverse transcriptase inhibitors (RTi's) that have been widely used for treating HIV and hepatitis B. Since this class of drugs has been in the clinic for over 3 decades, there are significant data supporting their post-approval safety for long-term use. However, this has not been specifically addressed in the target population - patients with mild cognitive impairment (MCI), particularly women - who are underrepresented in HIV datasets.
This proposed Phase I safety trial will perform a Special Population Study in a cohort of MCI patients who may benefit from the intervention.
This study aims to (1) evaluate the safety and tolerability of standard dose FTC or Descovy for 3 months in MCI patients; (2) as secondary aims, collect preliminary data on clinical effects of standard dose FTC or Descovy compared to placebo for 3 months on cogntiive function in MCI patients; and (3) collect preliminary data on clinical effects of standard dose FTC or Descovy compared with placebo on AD-associated inflammatory markers.
Participants will be randomized into either Descovy or FTC arms in equal numbers, and receive either active drug or placebo. Participants will orally ingest 1 capsule or tablet (depending on drug arm) daily for the 3 month participation period.
The investigators hypothesise that MCI are not at increased risk of adverse effects due to administration of standard dose FTC or Descovy.

Start Date30 Jun 2025

Sponsor / Collaborator

National University Hospital

100 Clinical Results associated with Emtricitabine

100 Translational Medicine associated with Emtricitabine

100 Patents (Medical) associated with Emtricitabine

4,932

Literatures (Medical) associated with Emtricitabine

01 Mar 2026·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in naïve people living with HIV of Asian OrigiN (DRAGON)

Article

Author: Hsih, Wen-Hsin ; Lai, Hsin-Hao ; Zou, Meiyin ; Huang, Miao-Hui ; Lee, Shu-Yuan ; Zhao, Qingxia ; Zhang, Xue ; Yang, Chia-Jui ; Cheng, Chien-Yu ; Chen, Tsung-Chia ; Hung, Tung-Che ; Wu, Yi-Wen ; Lin, Yi-Chun ; Li, Linghua ; Cheng, Shu-Hsing ; Chen, Cheng-Pin ; Ma, Ping ; Tsai, Mao-Song ; Ho, Mao-Wang

OBJECTIVES:

Among people living with HIV (PWH), the use of integrase strand transfer inhibitors (INSTIs) has been increasingly linked to notable weight gain, raising clinical concern. Much of the available evidence originates from trials in Western regions and Africa, while observational data from Asian settings remain scarce.

METHODS:

This retrospective, multicenter cohort study analyzed treatment-naïve PWH at eleven HIV care centers in Taiwan and mainland China between 2019 and 2025. Treatment-naïve patients initiating dolutegravir/lamivudine (DTG/3TC) or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) were included. The primary endpoint was the proportion of patients with ≥10% weight gain. Secondary endpoints were virologic suppression (<200 copies/ml) between weeks 24-96 and changes in lipid profiles. Logistic regression with inverse probability weighting was used to identify the predictors of ≥10% weight gain.

RESULTS:

A total of 1087 patients were enrolled (DTG/3TC: 406; BIC/FTC/TAF: 681). Baseline CD4 counts were higher in the DTG/3TC group (315 vs 281 cells/µL, P = 0.01), while HIV RNA levels were lower (4.68 vs 4.96 log10 copies/ml, P < 0.01). Both regimens achieved comparable virologic suppression overall, including in participants presenting with advanced HIV disease. Weight gain was greater with BIC/FTC/TAF at week 48 (4.2 vs 2.2 kg; difference 2.0 kg; 95% CI: 1.1-2.9; P < 0.01) and week 96 (5.1 vs 2.8 kg; difference 2.3 kg; 95% CI: -1.1 to 3.5; P < 0.01). At week 48 and 96, 21.6% and 30.5% experienced ≥10% weight gain, respectively. After calculating IPTW, logistic regression analysis identified the following predictors included CD4 <200 cells/µL (aOR 2.54 and 2.89), BMI <24 kg/m² (aOR 2.59 and 2.35), and BIC/FTC/TAF (aOR 1.83 and 1.83) at week 48 and 96, respectively. At week 48 and 96, HDL cholesterol was significantly lower in the BIC/FTC/TAF group (mean differences = -2.4, and -2.4 mg/dl, respectively; P < 0.05).

CONCLUSION:

In this large real-world Asian cohort, BIC/FTC/TAF and DTG/3TC demonstrated comparable virological efficacy. However, TAF-containing regimen-particularly among individuals with lower CD4 counts and BMI-were associated with greater weight gain and attenuated increases in HDL cholesterol, highlighting the need for careful metabolic monitoring.

05 Feb 2026·Sexual Health

Daily PrEP and event-driven PrEP adherence for men who have sex with men in China

Article

Author: Qiu, Danwen ; Huang, Haojie ; Lio, Jonathan ; Yin, Zhuoheng ; Burns, Paul A. ; Teng, Fei ; Tang, Weiming ; Liang, Ke ; Walker, Benjamin ; Welsch, Michael A. ; Li, Linghua ; Tucker, Joseph D. ; Hazra, Aniruddha ; Li, Chunyan ; Sherer, Renslow

Background:

The HIV incidence among Chinese men who have sex with men (MSM) has still been high over the past decade. Despite HIV pre-exposure prophylaxis (PrEP) being an effective prevention strategy, few studies have examined PrEP uptake and adherence in China. This study examined PrEP initiation and adherence among Chinese MSM enrolled in a multi-site PrEP demonstration trial.

Methods:

Three-month data for this study were drawn from a PrEP demonstration project in Guangzhou and Wuhan, China. The project aimed to increase the engagement of MSM in China for HIV/STI screening, HIV risk reduction, and PrEP initiation and adherence through the use of a mobile phone app and community engagement with crowdsourcing of messages and study images. Part of the intervention was the provision of tenofovir/emtricitabine as PrEP through two types of modalities: (1) once-daily oral dose (Daily-PrEP), or (2) event-driven dose (i.e. the 2 + 1 + 1 approach, Event-Driven PrEP). The outcome of interest was PrEP adherence, defined as missing fewer than five pills in the past 30 days for Daily PrEP, and no missed doses for the Event-Driven PrEP regimen. Univariate and multivariate logistic regressions were conducted for data analyses.

Results:

A total of 927 individuals started PrEP, with follow-up data available for 650 people (70%) after 3 months. There were 593 men with a median age of 30 years (range 21–61 years) in this study. Of those people, 341 reported taking Daily-PrEP, and 93% (317/341) reported missing fewer than five pills in the past 30 days. Among 252 participants who reported taking the Event-Driven PrEP regimen, 61.5% (155/252) reported full adherence. Daily-PrEP users were more likely to report good adherence than Event-Driven PrEP users (OR 7.28, P < 0.0001, 95% CI: 4.28–12.39).

Conclusion:

We observed a higher adherence to daily PrEP compared with Event-Driven PrEP among a sample of MSM in China. Further research is needed to examine long-term PrEP adherence among MSM in China.

01 Feb 2026·SEXUALLY TRANSMITTED INFECTIONS

Acute hepatitis B following a switch to long-acting cabotegravir plus rilpivirine in an individual with a history of hepatitis B vaccination

Article

Author: Gemignani, Nicole ; Conti, Federico ; Valesecchi, Giada ; Piconi, Stefania ; Pontiggia, Silvia ; Molteni, Chiara ; Morena, Valentina ; Bottanelli, Martina

Injectable long-acting cabotegravir plus rilpivirine (CAB+RPV LA) is an effective treatment option for people living with HIV. Unlike regimens containing tenofovir with lamivudine (3TC) or emtricitabine (FTC), it lacks therapeutic activity against the hepatitis B virus, and hepatitis B vaccination is recommended for non-immune individuals. We present a case of acute hepatitis B after switching to CAB+RPV LA in a previously vaccinated individual.

244

News (Medical) associated with Emtricitabine

13 Jan 2026

·www.pharmaceutical-technology.com

JPM26: HIV pipeline dosing optionality gives Gilead advantage

Gilead’s CEO Daniel O’Day presented at the J.P. Morgan Healthcare Conference on 12 January. Image credit: ETIENNE LAURENT / AFP via Getty Images Gilead’s range of treatments and prevention for human immunodeficiency virus (HIV), both on the market and in the pipeline, provides the company a competitive edge, CEO Daniel O’Day believes. Speaking at the J.P. Morgan Healthcare Conference 2026, which is taking place in San Francisco from 12 to 15 January 2026, O’Day explained that in HIV, the company has seven candidates and combinations in the pipeline, offering a range of treatment options for patients in both treatment with anti-retroviral therapies (ART) and prevention with pre-exposure prophylaxis (PrEP), which all offer varying dosing schedules and administration methods. O’Day said: “We have significantly expanded and diversified our pipeline with a range of options because if there’s one thing we know in HIV, it’s that patients want options. People who want to prevent HIV want options that fit their life and their lifestyle, particularly as we have transformed this disease from a death sentence to a preventable long-term, chronic illness.” While the company has already made a name for itself in HIV, especially with its newest PrEP treatment Yeztugo (lenacapavir), which is a twice-yearly injectable PrEP that touted 100% and 99% protection against the virus in two Phase III trials, it is continuing to develop its pipeline. Seven Gilead candidates are either in trials or awaiting regulatory decisions. Lenacapavir is also marketed under the name Sulenca when used as an ART. This includes a daily oral treatment, which is a combination of Gilead’s bictegravir and lenacapavir (BIC/LEN), for which it expects a regulatory decision in H2 2026. Full data from the Phase III ARTISTRY programme is due to be released in H1 2026. The company also expects to present data from two Phase III trials (NCT06630286 and NCT06630299) of a weekly oral combination of MSD’s islatravir and Gilead’s lenacapavir in H1 2026, with hopes that this would prepare the company for a 2027 launch. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Back in PrEP, Gilead is hoping for a 2028 launch of its once-yearly lenacapavir , if the regimen demonstrates success in clinical trials. Following its launch of Yeztugo in the US in mid-2025, the drug brought in $150m in preliminary sales in 2025, meeting its 2025 guidance. The PrEP also has 85% payer coverage in the US, with it being available with a $0 copay on some policies. O’Day said: “We take our responsibility in terms of ending the epidemic very, very seriously, so in addition to making progress in this country with the Yeztugo launch, I am very pleased that lenacapavir was delivered for the first time ever in a sub-Saharan African country at the end of last year, in the same year as it was introduced in the US. That has never been done before. We know that two-thirds of HIV cases are in sub-Saharan Africa. If we don’t stop HIV everywhere, we won’t stop it anywhere.” On top of new launches, Gilead still has some protection of its marketed therapies, with its flagship HIV ART, Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide), not losing exclusivity until 2036. The company will lose exclusivity of Descovy (emtricitabine/tenofovir alafenamide) in 2031. GlobalData, the parent company of Pharmaceutical Technology , predicts a combined patient-based sales forecast for Yeztugo and Sulenca of $4.98bn in 2033. The HIV market across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) is forecast to grow at a compound annual growth rate (CAGR) of 1.9% from $26.5bn in 2023 to $32.1bn in 2033, forecasts GlobalData . Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.

Phase 3

12 Jan 2026

·www.mddionline.com

Edwards Cancels JenaValve Acquisition After Court Sides with FTC

Edwards Lifesciences is backing out of its plan to acquire JenaValve. The move comes after the Federal Trade Commission won a ruling, late last week, that blocked the Irvine, CA-based company’s acquisition of JenaValve, according to a report from Reuters . In a release , Edwards said it disagreed with the decision and believed the acquisition would have been in the best interest of a large, growing, and underserved group of patients. Edwards first announced the deal in July of 2024. It was during this time that the company announced a flurry of deals, which included upfront capital commitments to Affluent Medical (€15 million stake, about $16.3 million); Innovalve Bio Medical ($300 million); and Endotronix . FTC would go on to challenge the acquisition in August of 2025 . The agency noted that such a deal would decrease competition in the market for a device that could treat a potentially fatal heart condition. Irvine, CA-based JenaValve has pioneered the transcatheter treatment of aortic regurgitation and heart failure patients. The company is developing the JenaValve Trilogy Heart Valve System and is still working to obtain approval of the device. Edwards said it will continue to deliver novel therapies and world-class evidence to transform patient care, including advancing the Sojourn transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial. As a result, Edwards said it is revising its full-year 2026 adjusted EPS guidance to $2.90 to $3.05, up from its earlier guidance of $2.80 to $2.95. The company noted that additional updates will be provided at the 4Q26 Earnings Call in February.

Acquisition

16 Dec 2025

·www.fiercepharma.com

Gilead's single-tablet HIV combo of bictegravir, lenacapavir passes another late-stage test on way to filings

The Artistry-2 win comes a month after Gilead reported a separate positive trial result for the investigational regimen. With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen.In Gilead's Artistry-2 study, the company's single-tablet regimen of bictegravir and lenacapavir matched up to Gilead's own megablockbuster HIV medicine Biktarvy when assessing patients' treatment responses, Gilead said in a Dec. 15 release. The trial enrolled adults with HIV who had achieved virologic suppression on Biktarvy and randomized them 2-1 to either switch to the novel regimen or continue receiving Biktarvy.In top-line results shared Monday, Gilead said the bictegravir 75-mg/lenacapavir 50-mg regimen was noninferior to Biktarvy, meeting the trial's primary endpoint. The primary endpoint looked at the percentage of participants with HIV-1 RNA levels ≥50 copies/mL at Week 48. The investigational combo was generally well tolerated, Gilead added.“These data support the potential of BIC/LEN as a meaningful additional treatment option for adults with HIV who are virologically suppressed," Gilead's Jared Baeten, M.D., Ph.D., senior vice president of clinical development and virology therapeutic area head, said in a statement. "We look forward to sharing the full Phase 3 data from the ARTISTRY-1 and ARTISTRY-2 trials next year and submitting these data for regulatory approval.”The news comes about a month after Gilead reported a top-line win in the Artistry-1 study. The trials were similar in design, but Artistry-1 enrolled patients who were on complex multi-tablet regimens at baseline. Bictegravir, an integrase strand transfer inhibitor, is one of the three active ingredients in Biktarvy, alongside the antivirals emtricitabine and tenofovir alafenamide. Lenacapavir is a capsid inhibitor used in the company's long-acting HIV treatment Sunlenca and its twice-yearly PrEP drug Yeztugo.When Gilead reported the Artistry-1 win, Citi analyst Geoffrey Meacham, Ph.D., wrote that the novel regimen "targets a key unmet need within the HIV market (~6-8%), who are not candidates for the standard-of-care" drug Biktarvy. Thus, the combo could allow Gilead to expand its reach in HIV without "cannibalizing its flagship product," Meacham wrote.In the wake of the Artistry-2 readout, Meacham explained in a note to clients that the novel offering could find use in the "Biktarvy switch market." "Indeed, today's positive results will enable Gilead to position the combo strategically and retain patients who might otherwise switch to other 2 drug regimen," Meacham wrote. "Overall the positive results across both ARTISTRY (1&2) trials will allow Gilead to provide a simplified 2-drug regimen and provide an alternative for the specific market segments that prefer fewer medications."Meacham's team is projecting 2030 sales of $630 million for the combo product. After planned filings next year, Gilead could launch the drug in 2027, the analyst wrote.

Clinical ResultPhase 3

100 Deals associated with Emtricitabine

External Link

KEGG	Wiki	ATC	Drug Bank
D01199	Emtricitabine	J05AF09	DB00879

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Gilead Sciences, Inc.	02 Jul 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aicardi-Goutieres Syndrome	Phase 2	-	Gilead Sciences, Inc.	01 Dec 2025
Hepatitis C	Phase 2	United States	Gilead Sciences, Inc.	01 Mar 2012
Hepatitis C, Chronic	Phase 2	United States	Gilead Sciences, Inc.	01 Mar 2012
Pregnancy	Phase 2	Cambodia	Gilead Sciences, Inc.	01 Oct 2006
Pregnancy	Phase 2	Côte d'Ivoire	Gilead Sciences, Inc.	01 Oct 2006
Pregnancy	Phase 2	South Africa	Gilead Sciences, Inc.	01 Oct 2006
Hepatitis B, Chronic	Phase 2	United States	Gilead Sciences, Inc.	01 Mar 2006
Hepatitis B, Chronic	Phase 2	France	Gilead Sciences, Inc.	01 Mar 2006
Hepatitis B, Chronic	Phase 2	Germany	Gilead Sciences, Inc.	01 Mar 2006
Hepatitis B, Chronic	Phase 2	Spain	Gilead Sciences, Inc.	01 Mar 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02150993 (FIT-2, Pubmed) Manual	Phase 2	HIV Infections First line	210	Tenofovir-boEmtricitabineirLamivudineZidovudine	trkokokbkl(whezhjlkxq) = gooyqxckux iijsthyxyd (tqqxugaako ) View more	Positive	01 Jun 2024
				tenofovirirEmtricitabineLamivudine	qbosodjnrr(qjfwepmrdr) = xlmbzhvnak ffmaglxpcw (efgrrcyddj, 47 - 66) View more
Rainbow study (Pubmed \| Int J Antimicrob Agents)	Phase 4	HIV Infections HIV-RNA	30	BIC/FTC/TAF	aqypmnohqz(tvifykmskt) = Two participants developed IRIS ixwuwmdthg (xntvnphlte ) View more	Positive	01 Jan 2024
NCT03917420 (CTgov)	Phase 1	Acquired Immunodeficiency Syndrome	10	Tenofovir 300Mg Oral Tablet+Emtricitabine 200 MG	dmfodtrapn(xwhznrssiw) = ydtvxitfcn hpkuinjwxy (mlqeskhean, 819.0428) View more	-	12 Apr 2023
FAST study—IMEA 055 (Pubmed \| J Antimicrob Chemother)	Not Applicable	-	112	Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	xpuonjkuwt(wbfkuhugig) = vovxidnths qeqtcmwkpu (lmintjqrzw ) View more	Positive	02 Mar 2023
NCT03348163 ((mo)BETTA, CTgov)	Phase 4	HIV Infections	26	B+TAF+FTC (Switch ART)	mocpvmjijz = bhiaeseyyw caonhneyof (hmnbiosmgy, mlmocsmjcb - ctdczjygww) View more	-	03 Oct 2022
				Current ART (Continue Current ART)	mocpvmjijz = jgdvgjaynd caonhneyof (hmnbiosmgy, iqpixdhcxl - svhjivjbko) View more
SIMPLâ??HIV (IAS2022)	Not Applicable	Maintenance	187	Dolutegravir plus Emtricitabine	ipqlbgghyj(rajhkkdiof) = kbiixkphsl pjflprrixn (bjjbxcxhvw ) View more	Positive	01 Jan 2022
				Combined Antiretroviral Therapy	ipqlbgghyj(rajhkkdiof) = noxapdnwao pjflprrixn (bjjbxcxhvw ) View more
NCT03350672 (CTgov)	Phase 4	HIV Infections	37	TAF+FTC (Cohort 1b)	apnfoqghjx = ddirrssgds aoqmkqfben (yhzxywqanf, ybslvlflev - pxludojsah) View more	-	30 Sep 2021
				TAF+FTC (Cohort 1a)	gvqzbjceia = yhvtmnehqi sahoouglkx (xsyddytsex, npyaowqsfa - dbwgpjwycp) View more
IAS2021	Not Applicable	-	86	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)	yluyxmoefw(hdymszlqjl) = Median CD4 counts were stable fevkmysujc (njbijmkohr )	-	01 Jan 2021
NCT01335620 (CTgov)	Phase 4	HIV Infections	19	Truvada+Raltegravir	gnyktxphdh(xodnjlbzyd) = koksdmtzge bnmupboclj (begzpvbtzy, yqxauwinfx - lwmwixjniu) View more	-	20 Nov 2019
NCT02616783 (Pubmed) Manual	Phase 3	HIV Infections	167	Emtricitabine+Tenofovir+Elvitegravir+Cobicistat	ueztbqrpli(qprtozxeok) = qescxxvbwn xiwjkgobam (opfwxptojb, 2.20) View more	Superior	01 Oct 2019
				therapy containing tenofovir disoproxil fumarate	ueztbqrpli(qprtozxeok) = jvbmowrvqe xiwjkgobam (opfwxptojb, 2.20) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis